Workflow
宁科生物(600165) - 2014 Q1 - 季度财报
NSWRCNSWRC(SH:600165)2014-04-29 16:00

Financial Performance - Net profit attributable to shareholders increased significantly by 1,600.06% to CNY 59,284,009.57 from CNY 3,487,173.24 in the same period last year[9] - Basic earnings per share increased to CNY 0.216 from CNY 0.013, representing a growth of 1,561.54%[9] - Operating profit for the current period is ¥64,383,538.00, compared to a loss of ¥6,388,126.06 in the previous period[30] - Net profit for the current period is ¥58,226,644.23, a significant increase from ¥2,234,487.77 in the previous period[30] - The company reported a total comprehensive income of ¥58,226,644.23 for the current period[31] Revenue and Costs - Operating revenue decreased by 1.12% to CNY 356,823,514.80 compared to CNY 360,852,681.65 in the previous year[9] - Total operating revenue for the current period is ¥356,823,514.80, a decrease of 1.4% from ¥360,852,681.65 in the previous period[30] - Total operating costs increased to ¥379,181,858.28, up 3.4% from ¥367,240,807.71 in the previous period[30] Cash Flow - Net cash flow from operating activities improved to CNY 19,514,643.33, a significant recovery from a negative CNY 23,958,345.74 in the same period last year[9] - Cash flow from operating activities generated a net amount of ¥19,514,643.33, compared to a negative cash flow of ¥23,958,345.74 in the previous period[38] - Cash inflow from investment activities totaled ¥18,593,200.00, while cash outflow was ¥7,980,583.23, resulting in a net cash flow of ¥10,612,616.77[38] - Cash inflow from financing activities was ¥71,000,000.00, an increase from ¥47,700,000.00 in the previous period[38] Assets and Liabilities - Total assets increased by 0.71% to CNY 2,579,524,772.44 compared to the end of the previous year[9] - Current assets rose to CNY 1,678,803,933.04, up from CNY 1,543,391,273.92, indicating an increase of about 8.7%[21] - Total liabilities decreased to CNY 1,433,875,212.27 from CNY 1,474,087,905.81, a decline of about 2.7%[22] - Shareholders' equity increased to CNY 1,145,649,560.17 from CNY 1,087,274,592.80, reflecting a growth of approximately 5.4%[23] Shareholder Information - The number of shareholders at the end of the reporting period was 25,913[10] - The largest shareholder, Shanghai Xinri Equity Investment Co., Ltd., holds 29.20% of the shares, totaling 80,000,000 shares[10] Investments and Other Income - The company recorded a gain of CNY 87,163,823.00 from the transfer of equity in Lanzhou Bank[9] - The company’s investment income remained stable at ¥86,741,881.48, indicating a consistent performance in this area[13] - The company reported a decrease in other income, which fell to ¥1,001,446.64, down by ¥8,673,298.55 or 89.65% from the previous year[13] Expenses - Sales expenses rose to ¥20,243,894.67, an increase of ¥5,495,949.64 or 37.27% compared to the previous year[13] - Financial expenses increased to ¥15,826,582.35, up by ¥5,805,027.92, reflecting a rise of 57.93% year-over-year[13] Future Plans and Challenges - The company plans to issue short-term financing bonds, which was approved by the board and shareholders[15] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] - The company is facing significant litigation issues, including the freezing of shares held by the largest shareholder[16] - The company has committed to avoiding competitive activities with its major shareholders to reduce related party transactions[17]